{"id":231259,"date":"2020-12-04T12:18:57","date_gmt":"2020-12-04T17:18:57","guid":{"rendered":"https:\/\/oncubanews.com\/en\/?p=231259"},"modified":"2020-12-04T12:18:57","modified_gmt":"2020-12-04T17:18:57","slug":"clinical-trial-with-abdala-vaccine-candidate-begins-in-santiago-de-cuba","status":"publish","type":"post","link":"https:\/\/oncubanews.com\/en\/cuba\/clinical-trial-with-abdala-vaccine-candidate-begins-in-santiago-de-cuba\/","title":{"rendered":"Clinical trial with Abdala vaccine candidate begins in Santiago de Cuba"},"content":{"rendered":"

The clinical trial of the Abdala <\/span>vaccine candidate<\/span><\/a>, one of the four developed by Cuban scientists against <\/span>COVID-19<\/span><\/a>, began this Thursday at the General Saturnino Lora Hospital, in <\/span>Santiago de Cuba<\/span><\/a>.<\/span><\/p>\n

The director of that medical institution, Rafael Su\u00e1rez, explained that the study will consist of two phases and will involve 800 volunteers, according to <\/span>Prensa Latina<\/span><\/a><\/em> news agency.<\/span><\/p>\n

In the first phase\u2015which will run until February\u2015the vaccine candidate, one of the two developed by the Havana Center for Genetic Engineering and Biotechnology (CIGB), already approved for human studies, will be administered to 200 volunteers. In a second stage, the drug will be tested in another 600 participants, the source specified.<\/span><\/p>\n

https:\/\/twitter.com\/Gob_StgoDeCuba\/status\/1334595233477242886?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1334595233477242886%7Ctwgr%5E%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Foncubanews.com%2Fcuba%2Fcomienza-ensayo-clinico-con-candidato-vacunal-abdala-en-santiago-de-cuba%2F<\/p>\n

For the clinical trial, adults of both sexes, healthy or with controlled chronic diseases, residing in the southeastern city, were selected.<\/span><\/p>\n

In Su\u00e1rez\u2019s opinion, the selection of Santiago de Cuba to test the effectiveness of Abdala constitutes \u201crecognition\u201d for the results of that province in the battle against the COVID-19 epidemic\u2015despite the increase in cases detected in that province in recent weeks\u2015in addition to the experience of its institutions in previous medical studies, in particular those coordinated by the CIGB.<\/span><\/p>\n

Dr. Mar\u00eda del Carmen Ricardo will be the principal investigator of the trial of the COVID-19 vaccine candidate and will coordinate a team of specialists from the Santiago hospital, as well as from other scientific centers in the city such as the Oriente Pharmaceutical Laboratories and the Virology and Microbiology Laboratories.<\/span><\/p>\n

Last week, the Abdala and Mambisa vaccine projects, developed by the Havana CIGB, received the green light from the regulatory authority for Medicines, Equipment and Medical Devices in Cuba (CECMED) to begin human trials.<\/span><\/p>\n

Cuba autoriza ensayos cl\u00ednicos de dos nuevas vacunas contra la COVID-19<\/a><\/p><\/blockquote>\n